SOD3 and breast cancer: These changes were even more pronounced in breast cancer cells treated with an adenoviral EcSOD construct containing a deletion in the HBD, which eliminated the ability of EcSOD to associate with heparan sulfate and, therefore, its sequestration on the cell surface.